Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
8
×
life sciences
national
8
×
national blog main
san francisco top stories
national top stories
new york top stories
san francisco blog main
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york blog main
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
clinical trials
europe top stories
cancer
europe blog main
fda
novartis
pfizer
diagnostics
hepatitis b
medicare
merck
microbiome
What
drug
8
×
medicine
new
patients
bio
ceo
fda
market
marketing
plan
roundup
acquisitions
advantages
alex
amgen
amgen’s
anathema
announced
approval
approved
atrophy
awaited
bar
biggest
brings
build
buy
cancer
carries
cholesterol
collaboration
company’s
daily
daniel
debut
democrat
details
developed
discovery
drugs
Language
unset
8
×
Current search:
national
×
biotech
×
unset
×
drug
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
4 years ago
Pfizer Taps Insilico Medicine to Use AI for Drug Target Discovery
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
4 years ago
After First Look at House Drug Plan, Stocks Rise Slightly
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)